HOME PAGE | |
№ 2/2020
SALIKHOVA Olena Borysivna1, HONCHARENKO Daria Olehivna2
1Institute for Economics and Forecasting, NAS of Ukraine
2Ministry for Development of Economy, Trade and Agriculture of Ukraine
POLICY OF ENDOGENOUS DEVELOPMENT OF PHARMACEUTICALS IN CHINA: LESSONS FOR UKRAINE
Ekon. prognozuvannâ 2020; 2:139-157 | https://doi.org/10.15407/eip2020.02.139 |
ABSTRACT ▼
This article provides overview of the programs and plans, tools of scientific and technological, innovation and industry policies for new drug discovery. The authors substantiate that China has a government-led integrated approach to protecting and strengthening pharmaceutical sector. Discovered and proved the fact that the Chinese Government is encouraging R&D in the pharmaceutical sector, with special attention to the biotechnologies and is providing substantial support in the form of subsidies, tax incentives and establishment of special high-tech zones to encourage the production of new products and processes in the pharmaceutical sector. In addition to government support, there is substantial foreign direct investment in production and R&D, which entails transfer of technology and intensifies endogenous innovations in pharmaceutical manufacturing.
The authors give special attention to the fact that China’s Government Procurement provides domestic price preference programme and realizes policies promoting indigenous innovation products and technology transfer. Initiatives to create human resources for pharmaceuticals industry and government aid attract foreign specialists and highly qualified Chinese migrants. Government support has raised the level of production localization, and increased employment and value added in the industry. Among the achievements attained due to the political mechanisms created in this country, are scientific and technological competencies and technology development, and high competitiveness of the domestic pharmaceutical industry, protection of intellectual property rights, access to foreign markets, import substitution and lower dependence on imported technologies, pharmaceutical intermediate goods and end-product, and high consumer quality of manufactured goods.
It is proven that China’s state-led innovation and investment development model has supported growth over the last 40 years and produced numerous endogenous innovations in pharmaceutical manufacturing. The article presents the authors’ vision of the determinants of success of the Chinese government in building innovation potential of domestic pharmaceuticals industry and of the resilience of the industry in the face of crisis caused by COVID-19.
Keywords:China, pharmaceutical industry, biotechnologies, innovation, government aid, tax incentives, subsidies, public procurement, industrial policy
JEL: L52; L65; O14; O32
Article in Ukrainian (pp. 139 - 157) | Download | Downloads :528 |
REFERENCES ▼
2.Schwarz, P. (2020, April 13). European Union to spend half a trillion euros on imperialist interests in coronavirus bailout. World Socialist Web Site. Retrieved from www.wsws.org/en/articles/2020/04/13/euro-a13.html
3.The State of U. S. Science and Engineering 2020. NSF. Retrieved from ncses.nsf.gov/pubs/nsb20201
4.Profit of industrial enterprises monthly data review (2020). Macro events review, 1-3. Retrieved from pdf.dfcfw.com/pdf/H3_AP202004271378716988_1.pdf [in Chinese].
5.Korablin, S. (2019). China: investment ambitions, limitations and opportunities. Ekonomìka ì prognozuvannâ – Economy and forecasting, 3, 138-157. doi.org/10.15407/eip2019.03.138 [in Ukrainian].
6.Prudka, O. (2017). Chinese experience of state stimulation of innovation activity Nauka, Tekhnologii, innovatcii – Science, technology, innovation, 4, 35-45 [in Ukrainian].
7.Holubka, V. (2016). Mechanisms of regulation of the pharmaceutical market in Ukraine. Dissertation abstract for the degree of candidate of economic sciences, specialty 08.00.03 - Economics and management of national economy. Ivan Franko National University of Lviv [in Ukrainian].
8.Heyets, V., Scrypnychenko, M. (2003). From exogenously dependent to endogenously oriented economic development strategy. Ekonomìka ì prognozuvannâ – Economy and forecasting, 1, 34-46 [in Ukrainian].
9.Heyets, V., (2018). Endogenization of the economy development in the aspect of equality of rights relations among the state, business and voting subjects. Ekonomika Ukrainy – Economy of Ukraine, 7, 3-19. doi.org/10.15407/economyukr.2018.07.003 [in Ukrainian].
10.Salikhova, O.B. (2012). Hightech Industries: From Assessment Methodology to Growth in Ukraine. Kyiv [in Ukrainian].
11.Feigenbaum, Evan A. (1999). Who's Behind China's High-Technology “Revolution”? How Bomb Makers Remade Beijing's Priorities, Policies, and Institutions. International Security, 24: 1, 95-126. doi.org/10.1162/016228899560068
12.Introduction of Yaodu. Retrieved January 21, 2020 from www.cnmc.gov.cn/ [in Chinese].
13.Response from the National Development and Reform Commission to the approval of Liaoning Yaodu Development Co., Ltd. issue of corporate bonds (2019). Corporate Bonds Development and Reform, 132. Retrieved from www.ndrc.gov.cn/xxgk/zcfb/qt/201909/t20190929_1181955.html [in Chinese].
14.Plan of the national medium and long term development for science and technology (2006–2020). Retrieved from ww.gov.cn/jrzg/2006-02/09/content_183787.htmw [in Chinese].
15.A new special project to create medicines for the benefit of human health. Retrieved from www.gov.cn/zhengce/2018-10/10/content_5329091.htm [in Chinese].
16.Great achievements in major national scientific and technical projects for the creation of new drugs. Retrieved from www.gov.cn/xinwen/2019-08/01/content_5417723.htm [in Chinese].
17.Notice of the State Council for Press and Distribution "Made in China 2025" (2015). Guo Fa, 28. Retrieved from www.gov.cn/zhengce/content/2015-05/19/content_9784.htm [in Chinese].
18.Notice from the six print and distribution departments of the Pharmaceutical Industry Development Planning Guide. Retrieved from www.gov.cn/xinwen/2016-11/09/content_5130391.htm [in Chinese].
19.Salikhova, O. (2020, February 25) Turbo Nannies. Levyy bereg. Ukrayna – LB.ua. Retrieved from lb.ua/economics/2020/02/25/450866_turbonyani_.html [in Ukrainian].
20.High-tech industries supported by the state. Retrieved from www.waizi.org.cn/law/6441.html [in Chinese].
21.Liu, Huiling, Xing, Fei, Yakshtas, Kseniya, and Li, Bo (2018, December 13). Does the high-tech enterprise certification policy promote innovation in China? Economics-ejournal. Retrieved from www.economics-ejournal.org/economics/discussionpapers/2018-85
22.Salikhova, O. (2007). Methodical approaches to the assessment of the production potential of high-tech products competitive in the world market in Ukraine. Nauka ta naukoznavstvo – Science and science knowledge, 4, Annex C, 130-134 [in Ukrainian].
23.Salikhova, O. (2011). Targeted state support as a factor stimulating the development of high-tech industries in Ukraine. Ekonomìka ì prognozuvannâ – Economy and forecasting, 2, 9-23 [in Ukrainian].
24.Ministry of Finance, General Directorate of Taxation, Ministry of Science and Technology, Notification of an increase in the pre-tax deduction rate before taxes on research and development costs (2018). Tsai Shui, 99. Retrieved from www.chinatax.gov.cn/n810341/n810755/c3754895/content.html [in Chinese].
25.An announcement by the State Tax Administration on current tax policy issues regarding accelerated depreciation of fixed assets. Announcement No. 64 of 2014. Retrieved from www.chinaacc.com/zyssfg/hu2014111718511263263436.shtml [in Chinese].
26.Catalog of industries in which are foreign investment is encouraged (2019 edition). Retrieved from www.pkulaw.com/chl/2e6fab8549042788bdfb.html [in Chinese].
27.Qing Xia, Vicky, Cai Yang, Leo (2018, April 1). Contract BioManufacturing in China: Creating a New Segment. Contractpharma. Retrieved from www.contractpharma.com/issues/2018-04-01/view_features/contract-biomanufacturing-in-china-creating-a-new-segment/
28.Creation of scientific and technological talents. Retrieved from www.gov.cn/gzdt/att/att/site1/20120428/001e3741a558110595fa01.pdf [in Chinese].
29.UNESCO science report: towards 2030 (2017). Luxembourg: UNESCO Publishing United Nations [in Russian].
30.Government Procurement Law of the People's Republic of China (Revised in 2014). Retrieved from fgw.yinchuan.gov.cn/fgzc/flfg/201812/t20181221_1224321.htm [in Chinese].
31.Notice to the National Health Commission on the press and distribution of interim public procurement management measures (2018). Guowei Finance Development, 17. Retrieved from www.waizi.org.cn/doc/38884.html [in Chinese].
32.Public Procurement in China: European Business Experiences Competing for Public Contracts in China (2011). Public Procurement Study. European Chamber. Retrieved from cbi.typepad.com/files/euccc-public-procurement-in-china-april-2011.pdf
33.Notification to the Ministry of Finance of the press and distribution of measures to evaluate public procurement of endogenous innovative products (2007). Caiku. 30. Retrieved from www.gov.cn/ztzl/kjfzgh/content_883671.htm [in Chinese].
34.Notice of the Ministry of Finance on the Measures for the Administration of Government Procurement Contracts for endogenous Innovation Products (2007). Treasury, 31. Retrieved from big5.www.gov.cn/gate/big5/www.gov.cn/ztzl/kjfzgh/content_883701.htm [in Chinese].
35.China Statistical Yearbook-2019. Retrieved April 17, 2020 from www.stats.gov.cn/ [in Chinese].
36.China Statistical Yearbook-2007. Retrieved April 17, 2020 from www.stats.gov.cn [in Chinese].
№ 4/2020
SALIKHOVA Olena Borysivna1, HONCHARENKO Daria Olehivna2
1Institute for Economics and Forecasting, NAS of Ukraine
2Ministry for Development of Economy, Trade and Agriculture of Ukraine
UKRAINE'S PHARMACEUTICALS: FROM DEPENDENCE TO ENDOGENOUS DEVELOPMENT
Ekon. prognozuvannâ 2020; 4:7-35 | https://doi.org/10.15407/eip2020.04.007 |
ABSTRACT ▼
The article substantiates various theoretical and applied principles of developing high-tech pharmaceutical industries (HTPI). It is established that the key problem of developing countries in this area is the dependence on resources and markets of developed countries, while the involvement of advanced foreign technologies can be a catalyst for increasing the technological potential of host countries (subject to the availability of proper knowledge and human capital, changes in the institutional environment, and improved the framework conditions for innovation). In the context of the development of HTPI, the author shows the importance of the network nature of the acquisition by pharmaceutical companies of sustainable competitive advantages based on resources that are difficult to simulate or replace. It is substantiated that networks built with local research institutions, higher education institutions, and research units of other companies, give pharmaceutical manufacturers the opportunity to access complementary assets and become their specific resource, which provides unique competitive advantages.
The author reveals various methodological and statistical features of the categorization of industries by the level of technology in the conditions of globalization. It is substantiated that the current low value of the ratio of research and development (R&D) to value-added generated by pharmaceuticals of individual countries is not a sign of the industry’s low technological level, as the current revenues are the result of long-term R&D and harmonization procedures for launching new drugs with lags of 10-15 years.
A new tool for the study of international trade in high-tech pharmaceuticals is proposed, whose peculiar feature consists in the categorization of nomenclature items by end use; the List of high-tech medical and pharmaceutical intermediate goods is formulated (in accordance with SITC Rev.4 and UKT FEA); the following indicators are proposed: the coefficient of import dependence of pharmaceutical production, the coefficient of "purified" exports of pharmaceutical products and the coefficient of imports coverage with HTPI output, and the formulas for their calculation are provided. The author's approach is the first to create the opportunity to assess the scale of costs and the dependence of the pharmaceutical industry on imported components that embody advanced technologies and are the industrial supplies for HTPI.
It was found that in Ukraine the share of foreign intermediate high-tech goods in the consumption of the industry reaches 82.2%; the industry, working on imported substances, produces mainly products for the domestic market, without earning foreign currency, even to cover the cost of purchasing the necessary ingredients; manufacturers do not rely on synthesized chemical products of domestic production, primarily due to the fact that the products of the chemical industry for the needs of pharmaceuticals in Ukraine are virtually non-existent; and the increase in output depends on foreign technologies and intermediate goods. It is substantiated that Ukraine’s pharmaceutical industry is critically dependent on imported supplies to ensure the smooth operation of enterprises and the healthcare industry.
Key endogenous barriers that hinder the development of HTPI have been identified, including problems in the training of specialists and a lack of scientists whose competencies would contribute to solving the problems of endogenous development of the industry; lack of state aid to business entities for research, and technological and innovative activities; lack of own funds to increase expenditures on R&D and implementation of large-scale investment and innovation projects; and lack of cheap loans, due to which Ukrainian pharmaceutical manufacturers find themselves in unequal conditions compared to foreign competitors.
Conceptual bases of HTPI development in Ukraine are proposed; justified the expediency of legal changes, definition of strategic priorities and introduction of measures of development of HTPI in Ukraine based on the comprehensive approach, which will cover creation and development of pharmaceutical ingredients for medicines (chemical and biotechnological goods), medical products, fillers, packing materials, machinery and equipment for pharmaceuticals to help reduce the dependence on foreign technologies, and to increase the level of production localization, employment and revenues to the budgets of all levels.
Keywords:high-tech production, pharmaceuticals, industry, technologies, innovations, endogenous innovations, technological dependence, state policy
JEL: L52; L65; O14; O32
Article in Ukrainian (pp. 7 - 35) | Download | Downloads :526 |
REFERENCES ▼
2. A New Industrial Strategy for Europe. Brussels, 10.3.2020 COM(2020) 102 final. Retrieved from ec.europa.eu/info/sites/info/files/ communicationeu-industrial-strategy-march-2020_en.pdf [in English].
3. Pharmaceuticals – safe and affordable medicines (new EU strategy). Retrieved from ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordablemedicines
4. Covid-19 exposes EU’s reliance on drug imports. Retrieved from www.ft.com/content/c30eb13a-f49e-4d42-b2a8-1c6f70bb4d55
5. Heуets, V.M. (2018). Endogenization of the Economy Development in the Aspect of Equality of Rights Relations among the State, Business and Voting Subjects. Ekonomika Ukrainy – Economy of Ukraine, 7, 3-19. doi.org/10.15407/economyukr.2018.07.003 [in Ukrainian].
6. Vishnevskiy, V.P. et al. (2013). Industrial Policy and Management of Industrial Development in the Context of Systemic Imbalances: Conceptual Foundations. Donetsk [in Russian].
7. Kindzerskyi, Yu.V. (2016). Anti-crisis industrial policy: variant of the domestic concept. Visnyk Natsionalnoi akademii nauk Ukrainy – Bulletin of the National Academy of Sciences of Ukraine, 10, 27-42. doi.org/10.15407/visn2016.10.027 [in Ukrainian].
8. Dorovskyi, O.V. (2015). Justification of the Choice of Strategy for the Development of the Pharmaceutical Industry of Ukraine: avtoref. dys ... d-ra ekon. nauk : 08.00.03. Kharkiv [in Ukrainian].
9. Kostiuk, H., and Marhitych, V. On the National Drug Supply Strategy in Ukraine. Dzerkalo tyzhnia – Mirror of week. January 20, 2017. Retrieved from zn.ua/ukr/promyshliennost/ pro-nacionalnu-strategiyu-zabezpechennya-likami-vukrayini-_.html
10. Discussion of the Draft Strategy for the Development of the Pharmaceutical Industry of Ukraine for 2010-2020 (May 18, 2010). Retrieved from oormmpu.at.ua/news/obgovorennja_proektu_strategiji_rozvitku_farmacevtichnoji_promislovosti_ukrajini_na_2010_2020_roki/2010- 05-18-124
11. Deineko L.V. (Ed.). (2018). Development of Industry to Ensure the Growth and Renewal of the Ukrainian Economy. Institute for Economics and Forecasting of the NAS of Ukraine, Kyiv [in Ukrainian].
12. Salikhova, O.B., and Honcharenko, D.O. (2020). Politics of development of pharmaceutical industry inGermany: Lessons for Ukraine. Ekonomika Ukrainy – Economy of Ukraine, 10, 63-86. doi.org/10.15407/economyukr.2020.10.063 [in Ukrainian].
13. Salikhova, O.B., and Honcharenko, D.O. (2020). The Pharmaceutical Industry of France. Zovnishnia torhivlia: ekonomika, finansy, pravo – Foreign trade: economy, finances, right, 2, 67-84. doi.org/10.31617/zt.knute.2020(109)05 [in Ukrainian].
14. On approval of the State program of economic stimulation to overcome the negative consequences caused by restrictive measures to prevent the occurrence and spread of acute respiratory disease COVID-19 caused by coronavirus SARS-CoV-2, for 2020-2022. Retrieved from www.kmu.gov.ua/npas/pro-zatverdzhennya-derzhavnoyi-programi-stimulyuvannya-ekonomiki-534-270520 [in Ukrainian].
15. Gerschenkron, A. (1962). Economic Backwardness in Historical Perspective. Cambridge: The Belknap Press of Harvard University.
16. Salikhova, O.B., and Honcharenko, D.O. (2020). Policy of Endogenous Development of Pharmaceuticals in China: Lessons for Ukraine. Ekon. prognozuvannâ – Economy and forecasting, 2, 139-157. doi.org/10.15407/eip2020.02.139 [in Ukrainian].
17. Veblen, T. Imperial Germany and Th e Industrial Revolution. Retrieved from core.ac.uk/download/pdf/7048899.pdf
18. Honcharenko, D.O. (2020). New Approaches to the Assessment of Foreign Trade in High-Tech Pharmaceuticals. Statystyka Ukrainy – Statistics of Ukraine, 1, 35-41. doi.org/10.31767/ su.1(88)2020.01.04
19. Salikhova, O., and Bak, G. (2015). Concepts of the influence of technology transfer by transnational corporations on the economy of a recipient country. Ìstor. nar. gospod. ekon. dumki Ukr. – History of economics and economic thought of Ukraine, 48, 270-295 [in Ukrainian].
20. Heуets, V.M. (2014). Institutional conditionality of innovative processes in ukraine’s industrial development. Ekonomika Ukrainy – Economy of Ukraine, 12, 4-19 [in Ukrainian].
21. Salikhova, O.B., and Honcharenko, D.O. (2020). Pharmaceutical industry of Mexico: a lesson for Ukraine. Zovnishnia torhivlia: ekonomika, finansy, pravo – Foreign trade: economy, finances, right, 7, 47-69 [in Ukrainian].
22. Crafts, N.F.R. (1995, Dec.). Exogenous or Endogenous Growth? The Industrial Revolution Reconsidered. The Journal of Economic History, 55: 4, 745-772. doi.org/10.1017/S0022050700042145
23. Simurina, J., Tolic, I. (2008, January). Dynamics of the technology progress in economic development . Ekonomska Istraživanja/ Economic Research, 21(3), 12-24.
24. Mayer, J. (1996, December). Implications of new trade and endogenous growth theories for diversification policies of commodity-dependent countries, 122. UNCTAD/OSG/DP/122. Retrieved from core.ac.uk/download/pdf/7043238.pdf
25. Romer, Paul M. (1990, Oct.). Endogenous Technological Change. Journal of Political Economy, 98: 5, p. 71-102. Retrieved from web.stanford.edu/~klenow/Romer_1990.pdf; doi.org/10.1086/261725
26. Romer, Paul M. (1987, May). Growth Based on Increasing Returns Due to Specialization. The American Economic Review, 77: 2, 56-62. Retrieved from eclass.uoa.gr/modules/document/file.php/ECON206/Course%20material/Romer%20Growth%20Increasing%20Returns%20AER%201987.pdf
27. Grossman, Gene M., Helpman, E. (2018, January). Growth, trade and inequality. Econometrica, 86: 1, 37-83. Retrieved from www.princeton.edu/~grossman/GrowthTradeInequality.pdf;
doi.org/10.3982/ECTA14518
28. Salikhova, O.B., Honcharenko, D.O. (2020). The Conceptual Foundations of the Strategy of Development of the High-Tech Industry of Pharmaceuticals and Medical Products in Ukraine till 2030. Biznes Inform – Business Inform, 7, 28-35. Retrieved from doi.org/10.32983/2222-4459-2020-7-28-35 [in Ukrainian].
29. Frascati, M. (2002). Proposed Standard Practice for Surveys on Research and Experimental Development. Paris: OECD.
30. Salikhova, O. (2012). High-tech Industries: From Evaluation Methodology to Rise in Ukraine. Institute for Economics and Forecasting, NAS of Ukraine. Kyiv [in Ukrainian].
31. Annual detailed enterprise statistics for industry (NACE Rev. 2, B-E). European Commission. Retrieved from ec.europa.eu/
32. Business expenditure on R&D (BERD) by NACE Rev. 2 activity. Retrieved from ec.europa.eu/
33. Corporation tax in the Republic of Ireland. Retrieved from en.wikipedia.org/wiki/Corporation_tax_in_the_Republic_of_Ireland
34. Why Ireland Is Attracting The World’s Top Pharmaceutical Companies and How You Can Benefit. Retrieved from www.innopharmaeducation.com/news/why-ireland-attracting-the-worlds-top-pharmaceutical-companies-and-how-you-can-benefit
35. The Pharmaceutical Industry in Figures. Key Data 2020 (2020). Brussels: EFPIA. Retrieved from www.efpia.eu/media/554521/efpia_pharmafigures_2020_web.pdf
36. Evaluate Pharma® World Preview 2020, Outlook to 2026. Retrieved from info.evaluategroup.com/
37. Scientific and innovative activity of Ukraine in 2018. Retrieved from www.ukrstat.gov.ua/
38. Scientific and innovative activity of Ukraine in 2019. Retrieved from www.ukrstat.gov.ua/
39. Strategy for the development of medical education in Ukraine 27.02.2019. Retrieved from moz.gov.ua/uploads/1/8475-medical_education_analytics.pdf
40. National accounts of Ukraine for 2018. Retrieved from www.ukrstat.gov.ua/
41. Salikhova, O. (2011). High-tech capital goods in import structure of Ukraine. Economist – Economist, 9, 28-32. Retrieved from nbuv.gov.ua/UJRN/econ_2011_9_7
42. Salikhova, O. (2012). High Tech lmports to Ukraine and its Critical Determinants. Nauka ta naukoznavstvo – Science and science knowledge, 4, 40-56. Retrieved from dspace.nbuv.gov.ua/bitstream/handle/123456789/85921/05-Salikhova.pdf?sequence=1
43. UN Comtrade Database (2020). comtrade.un.org. Retrieved from comtrade.un.org/data/ [Appeal data: March 1. 2020].
44. Statistical Yearbook for 2018. Retrieved from www.ukrstat.gov.ua/druk/publicat/kat_u/2019/zb/11/zb_yearbook_2018.pdf
45. Science and Engineering Indicators 2020. Retrieved from nsf.gov/statistics/seind/
46. Global life sciences outlook. Focus and transform. Accelerating change in life sciences (2019). Retrieved from www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-ls-outlook-2019.pdf
№ 3/2021
SALIKHOVA Olena Borysivna1, HONCHARENKO Daria Olehivna2
1Institute for Economics and Forecasting, NAS of Ukraine
2Ministry for Development of Economy, Trade and Agriculture of Ukraine
CHALLENGES OF THE COVID-19 PANDEMIC TO PHARMACEUTICAL MANUFACTURING: THE EU AND UKRAINE’S RESPONSE
Ekon. prognozuvannâ 2021; 3:93-117 | https://doi.org/10.15407/eip2021.03.093 |
ABSTRACT ▼
The global COVID-19 pandemic, which has caused a shortage of medicines and medical products, as well as pharmaceutical products, especially active pharmaceutical ingredients, has demonstrated Ukraine’s unpreparedness to face such challenges and threats. This encourages the search for effective mechanisms to reduce vulnerability, ensure stability and develop pharmaceutical activities. The purpose of the article is to draw on the experience of the European Union to justify the need to introduce measures of the policy of stimulating the development of pharmaceuticals in Ukraine in order to reduce the dependence of the sector and the healthcare system on imports. To achieve the goal of the article, the authors used analysis and synthesis, logic-dialectic and comparative analysis methods. The article shows the nature and extent of existing dependencies of pharmaceutical production; and identifies features of the EU policy. The EU has been found to have a long history of prioritising and promoting pharmaceutical industry. It is shown that the new EU strategic documents adopted in response to the COVID-19 crisis have laid the foundation for the elimination of the industry’s vulnerabilities and external trade dependencies. For the first time, a conceptual approach to the formation of a dualist state policy and strategy for the development of Ukraine’s high-tech pharmaceutical production was proposed, which is based on synergies and complementary policies between drug policy and industrial policy. This approach is aimed both at stimulating the development and production of new pharmaceuticals based on advanced technologies and reducing the dependence of this country’s healthcare system on imports. Also, the approach aims at enhancing the competitiveness of pharmaceutical production, increased localization through the use of locally produced products, intensifying related activities, ensuring stability of supply of pharmaceutical products and transforming the industry into a strategic asset of growth of the economy, employment, and national security. The authors propose a conceptual approach to defining the priorities and programme tasks of the policy for the development of Ukrainian high-technology pharmaceutical production based on the principles of multi-dimensionality and comprehensiveness, and covering the development and production not only of medicines and medical products, but also of pharmaceutical ingredients (chemical and biotechnological), fillers and packaging materials, equipment and apparatus for pharmaceutical production. The principles of the formation of a strategy for the development of the high-tech pharmaceutical production of Ukraine are justified based on the balance of interests of consumers and producers of pharmaceutical goods with the interests of the State, based on its following goals: to care for the health of the nation, ensure an efficient economic system and social stability; promote the emergence of new effective drugs based on advanced technologies; and reduce dependence on imports and threats to national security.
Keywords:Eurointegration, pharmaceutical industry, pharmaceutical policy, industrial policy, technological dependence, high-tech manufacturing
JEL: L52; L65; O14; O32
Article in Ukrainian (pp. 93 - 117) | Download | Downloads :442 |
REFERENCES ▼
2. Salikhova, O.B. Honcharenko D.O. (2020). Ukraine's Pharmaceuticals: From Dependence to Endogenous Development. Ekon. prognozuvannâ – Economy and forecasting, 4, 7-35. doi.org/10.15407/eip2020.04.007 [in Ukrainian].
3. Open Appeal of the Association «Manufacturers of Medicines of Ukraine» to the President, Prime Minister, other high-ranking officials. Retrieved from ua.interfax.com.ua/news/press-release/651870.html
4. Chernykh, V. (2002) Pharmaceutical industry for the years of independence of Ukraine. Visnyk farmatsiyi – Herald of pharmacy, 3, 3-12 [in Ukrainian].
5. Hroshovyi, T., Pidhirnyi, V., Tryhubchak, O. (2011) Some issues of development of pharmaceutical branch of Ukraine. Zbirnyk prats' Ternopil's'koho oseredku Naukovoho tovarystva imeni Shevchenka – Collection of works of the Ternopil branch of the Scientific Society named after Shevchenko, 6, 154-172 [in Ukrainian].
6. Chomenko, V.N. (2008) Theoretical basis and implementation of modern principles of state pharmacy in Ukraine: avtoref. dys ... Dr in Pharm. Sciences : 15.00.01. Kharkiv [in Ukrainian].
7. Dorovskyi, O.V. (2015). Justification of the Choice of Strategy for the Development of the Pharmaceutical Industry of Ukraine: avtoref. dys ... Dr. in Economics: 08.00.03. Kharkiv [in Ukrainian].
8. Karamyshev, D.V., Sotnikova, L.V. (2021) Implementation of Ukraine’s State policy on the supply of medicines in the context of integration into the European Union. Teoriya ta praktyka derzhavnoho upravlinnya – Theory and practice of public administration, 1(72), 145-157 [in Ukrainian].
9. Sidenko, V.R. (2001) Conceptual foundations of Ukrainian Eurointegration strategy. Ekon. prognozuvannâ – Economy and forecasting, 2, 26-41 [in Ukrainian].
10. Kindzerskyi, Yu.V. (2021) Ukraine's industrial divergence with the EU and problems of it overcoming. Ekonomika ta derzhava – economy and state, 6, 9-18. doi.org/10.32702/2306-6806.2021.6.9 [in Ukrainian].
11. Korablin, S.О. (2021) Government Regulation As A Factor In Counteracting Covid-19. Ekonomika Ukrainy – Economy of Ukraine, 7, 27-40. doi.org/10.15407/economyukr.2021.07.027 [in Ukrainian].
12. Salikhova, O.B. (2021). Localization of pharmaceutical production in Europe as a response to growing external dependence. In Perspectives for post-coronavirus economic transformations and their impact on the development of countries. The place of Ukraine in the post-crisis world (p. 118-124). Kyiv: Zapovit [in Ukrainian].
13. Salikhova, O.B. Comparative advantages of national pharmaceutical industries through the prism of new indicators. Statystyka Ukrainy – Statistics of Ukraine, 2-3, 48-58. doi.org/10.31767/su.2-3(89-90)2020.02-03.06 [in Ukrainian].
14. EU unveils strategy to reduce dependency on China Retrieved from www.eiu.com/n/eu-unveils-strategy-to-reduce-dependency-on-china/
15. EC (2020, October 2). Special meeting of the European Council - Conclusions. Retrieved from www.consilium.europa.eu/media/45910/021020-euco-final-conclusions.pdf
16. Gereffi, G. (2017). The Pharmaceutical Industry and Dependency in the Third World. Princeton University Press.
17. Salikhova, O.B., and Honcharenko, D.O. (2020). Pharmaceutical industry of Mexico: a lesson for Ukraine. Zovnishnia torhivlia: ekonomika, finansy, pravo – Foreign trade: economy, finances, right, 7, 47-69 [in Ukrainian].
18. Chamarik, S. (1994). Goonatilake S.Technological independence - The Asian experience. The United Nations University. Retrieved from digitallibrary.un.org/record/177101
19. Woher kommen unsere Wirkstoffe? (2020, September). Eine Weltkarte der API-Produktion. Kurzreport. Pro Generika. Berlin [in German].
20. Arnum, Р. The EU’s API Supply Chain Under Focus. Retrieved from www.dcatvci.org/7143-the-eu-s-api-supply-chain-under-focus
21. Commission communication to the Council and Parliament on the outlines of an industrial policy for the pharmaceutical sector in the European Community (1994, March 2). COM (93) 718. Retrieved from op.europa.eu/mt/publication-detail/-/publication/6af1ca21-939d-11e9-9369-01aa75ed71a1/language-en/format-PDF/source-search
22. Council Resolution designed to implement the outlines of an industrial policy in the pharmaceutical sector in the European Union (1996). Retrieved from op.europa.eu/ga/publication-detail/-/publication/bf15f43c-6a8b-4953-8155-04fc004a1be3/language-en
23. EC, Commission Staff Working Document (2014). Pharmaceutical Industry: A Strategic Sector for the European Economy. etrieved from ec.europa.eu/growth/content/pharmaceutical-industry-strategic-sector-european-economy-0_en
24. Affordable, accessible and safe medicines for all: the Commission presents a Pharmaceutical Strategy for Europe. Retrieved from ec.europa.eu/commission/presscorner/detail/en/ip_20_2173
25. Updating the 2020 Industrial Strategy: towards a stronger Single Market for Europe's recovery. Retrieved from ec.europa.eu/commission/presscorner/detail/en/IP_21_1884
26. EU research and innovation in action against the coronavirus: funding, results and impact. Retrieved from ec.europa.eu/info/sites/default/files/research_and_innovation/research_by_area/documents/ec_rtd_eu-research-innovation-against-covid.pdf
27. INNO4COV-19 - Boosting Innovations for COVID-19 Diagnostic, Prevention and Surveillance. Retrieved from idw-online.de/de/news757837
28. EU Strategy for COVID-19 vaccines. Brussels (2020, July17). COM(2020) 245 final. Communication From The Commission To The European Parliament, The European Council, The Council And The European Investment Bank. Retrieved from eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52020DC0245&from=EN
29. Safe COVID-19 vaccines for Europeans. Retrieved from ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en#check-the-facts
30. COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics. Retrieved from ec.europa.eu/commission/presscorner/detail/en/ip_21_3299
31. Dujun (Honcharenko), D.О. (2016) Threats of the pharmaceutical production of Ukraine in the context of the analysis of foreign trade in high-technology goods. Problemy nauky – Problems of science, 2, 23-33 [in Ukrainian].
32. Recommendations of the Committee hearing of June 15, 2016 "Legislative Support for the Development of the National Innovation System: State and Solutions" (2016, June 15). Approved by the decision of the Verkhovna Rada Committee on Science and Education of 6 July 2016, Protocol 46. Retrieved from kno.rada.gov.ua/news/Robota_Kom/Parl_Kom_slukh/Kom_slukh/8_skl/74403.html [in Ukrainian].
33. Draft Concept of the State Target Programme Development of Import-substituting Industries in Ukraine and Substitution of Imported Medicines with Domestic Preparations, including Biotechnological Preparations and Vaccines for 2011-2021. Retrieved from www.apteka.ua/article/78579 [in Ukrainian].
34. Honcharenko, D.O. (2021). Development of pharmaceuticals of Ukraine in the conditions of European integration: principles, events, priorities. Integration of scientific research and development in practical activity: collection of materials of the III of the All-Ukrainian Multidisciplinary Scientific and Practical Internet Conference, June 30, 2021, Kharkiv (p. 30-38). Kyiv: Jarochenko Ja.V. doi.org/10.51500/7826-09-4 [in Ukrainian].
35. The concept of the development of import-substituting industries - a threat to the pharmaceutical industry and to the security of the population of Ukraine. Retrieved from ua.interfax.com.ua/news/press-release/68941.html [in Ukrainian].
36. The results of the implementation of the State scientific and technical programme for the development of the latest technologies for the creation of indigenous medicines in 2012 were summarized. Retrieved from www.apteka.ua/article/201885 [in Ukrainian].
37. Korj, B. Foundation at COVID-19: How used Coronavirus Money. Retrieved from voxukraine.org/fond-na-covid-19-yak-vikoristali-koronavirusni-groshi/ [in Ukrainian].
38. Draft Order of the Cabinet of Ministers of Ukraine "On approval of the Concept of the State Target Programme for the Creation and Development of the Internal Production of High-Quality Medicines for the Prevention and Treatment of Particularly Dangerous Infectious and Other Diseases in order to meet the State needs of Ukraine for the period 2021-2026. Retrieved from moz.gov.ua/ [in Ukrainian].
39. NAS of Ukraine (2021, June 9). Meeting of the Presidium of the NAS of Ukraine. Retrieved from www.nas.gov.ua/UA/Messages/Pages/View.aspx?MessageID=7891 [in Ukrainian].
40. Adoption of the National Economic Strategy 2030 (2021, March 3). Resolution of the Cabinet of Ministers of Ukraine 179. Retrieved from www.kmu.gov.ua/npas/pro-zatverdzhennya-nacionalnoyi-eko-a179 [in Ukrainian].
41. Simonov, D. Almost like going to Mars.
Could Ukraine develop its own coronavirus vaccine. Retrieved from hromadske.ua/posts/majzhe-yak-polit-na-mars-chi-mozhe-ukrayina-stvoriti-vlasnu-vakcinu-proti-koronavirusu [in Ukrainian].
42. There is a capacity to produce a vaccine against COVID in Ukraine – developers. Retrieved from www.radiosvoboda.org/a/meyemo-potuzhnosti-aby-vyhotovliaty-vaksinu-proty-covid-v-ukraini/30917997.html [in Ukrainian].
43. Salikhova, O.B., and Honcharenko, D.O. (2020). Politics of development of pharmaceutical industry in Germany: Lessons for Ukraine. Ekonomika Ukrainy – Economy of Ukraine, 10, 63-86. doi.org/10.15407/economyukr.2020.10.063 [in Ukrainian].
44. Honcharenko, D.O. (2021). The Theoretical Approaches and Methodological Principles for Development of Ukrainian Pharmaceutical Production in the Conditions of European Integration. Biznes Inform – Business Inform, 5, 194-201. doi.org/10.32983/2222-4459-2021-5-194-201 [in Ukrainian].
45. Salikhova, O.B., Honcharenko, D.O. (2020). The Conceptual Foundations of the Strategy of Development of the High-Tech Industry of Pharmaceuticals and Medical Products in Ukraine till 2030. Biznes Inform – Business Inform, 7, 28-35. doi.org/10.32983/2222-4459-2020-7-28-35 [in Ukrainian].
46. Salikhova, O.B., and Honcharenko, D.O. (2020). The Pharmaceutical Industry of France. Zovnishnia torhivlia: ekonomika, finansy, pravo – Foreign trade: economy, finances, right, 2, 67-84. doi.org/10.31617/zt.knute.2020(109)05 [in Ukrainian].
Events calendar
M | T | W | T | F | S | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 |
8 | 9 | 10 | 11 | 12 | 13 | 14 |
15 | 16 | 17 | 18 | 19 | 20 | 21 |
22 | 23 | 24 | 25 | 26 | 27 | 28 |
29 | 30 |